Are you or your loved ones suffering from multiple myeloma?

You may be eligible to participate in a multiple myeloma clinical trial.

Are you or your loved ones suffering from multiple myeloma? You may be eligible to participate in a multiple myeloma clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Multiple Myeloma
NCT02863991 | Phase 1 phase 2 | Interventional
Oncoceutics Inc
Sponsored by
Oncoceutics Inc

Are you or your loved ones suffering from multiple myeloma?

You may be eligible to participate in a multiple myeloma clinical trial.

Are you or your loved ones suffering from multiple myeloma? You may be eligible to participate in a multiple myeloma clinical trial.

Recruiting

Male & Female

18 +

years old

This study is looking to recruit 42 Participants

ONC201 is an orally bioavailable first-in-class small molecule with demonstrated antitumor activity in preclinical models of difficult-to-treat solid and liquid tumors without imparting significant toxicity. This is a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone to patients with relapsed/refractory multiple myeloma. Funding Source - FDA OOPD

Where you'll go

Selected location

Fox Chase Cancer Center

Fox Chase Cancer Center Change

333 Cottman Avenue, Philadelphia, PA, USA 19111

Carlyn Tan, MD 888-369-2427

Map | Learn more
Available locations
The Mount Sinai Medical Center

The Mount Sinai Medical Center

Recruiting New York, NY, USA 10029-6574

Interested in participating?
Selected location

Fox Chase Cancer Center

333 Cottman Avenue, Philadelphia, PA, USA 19111

Carlyn Tan, MD 888-369-2427


The information you provide is confidential and is never sold or shared with outside vendors. By clicking the button, you agree to the PatientWing's Terms and Privacy Policy.
Sign up now